Voyager Therapeutics Inc
For the period ended Sep 30, 2024. Filed Nov 12, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 12, 2024
VYGR$1.83-8.3%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(amounts in thousands)
| | | | | | | | |
|---|---|---|---|---|---|---|---|
| · · Nine Months Ended · | |||||||
| · · September 30, | |||||||
| · 2024 · 2023 | |||||||
| Cash flow from operating activities · · · · · | |||||||
| Net (loss) income | | $(30,515) | | $75,935 | | ||
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | | | | | | | |
| Stock-based compensation expense | | 11,048 | | 8,108 | | ||
| Depreciation | | 3,720 | | 3,106 | | ||
| Impairment charge on leased facility | | | 2,776 | | | — | |
| Amortization of premiums and discounts on marketable securities | | | (6,456) | | | (1,832) | |
| Loss on disposal of fixed assets | | 478 | | 143 | | ||
| Changes in operating assets and liabilities: | | | | | | | |
| Accounts receivable | | | 64,196 | | | — | |
| Related party collaboration receivable | | | (373) | | | (2,996) | |
| Prepaid expenses and other current assets | | (3,097) | | (342) | | ||
| Operating lease, right-of-use asset | | 3,423 | | 1,459 | | ||
| Accounts payable | | 1,556 | | 704 | | ||
| Accrued expenses | | (5,381) | | 3,236 | | ||
| Operating lease liabilities | | (1,698) | | (2,102) | | ||
| Deferred revenue | | (40,458) | | 16,260 | | ||
| Net cash (used in) provided by operating activities | | (781) | | 101,679 | | ||
| Cash flow from investing activities | | | | | | | |
| Purchases of property and equipment | | (3,366) | | (2,501) | | ||
| Purchases of marketable securities | | (334,667) | | (194,975) | | ||
| Proceeds from sales and maturities of marketable securities | | | 270,377 | | | 29,000 | |
| Net cash used in investing activities | | (67,656) | | (168,476) | | ||
| Cash flow from financing activities | | | | | | | |
| Proceeds from the exercise of stock options | | 261 | | 1,829 | | ||
| Proceeds from the issuance of common stock in connection with the underwritten public offering | | | 93,473 | | | — | |
| Proceeds from the issuance of common stock in connection with the 2023 Novartis Stock Purchase Agreement | | | 19,305 | | | — | |
| Proceeds from the issuance of common stock in connection with the 2023 Neurocrine Collaboration Agreement | | | — | | | 31,121 | |
| Proceeds from the purchase of common stock under ESPP | | | 402 | | | 235 | |
| Net cash provided by financing activities | | 113,441 | | 33,185 | | ||
| Net increase (decrease) in cash, cash equivalents, and restricted cash | | 45,004 | | (33,612) | | ||
| Cash, cash equivalents, and restricted cash, beginning of period | | 70,395 | | 100,474 | | ||
| Cash, cash equivalents, and restricted cash, end of period | | $115,399 | | $66,862 | | ||
| Supplemental disclosure of cash and non-cash activities | | | | | | | |
| Operating lease right-of-use asset obtained in exchange for operating lease liability | | $26,751 | | $— | | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.